← All Eyepoint Pharmaceuticals, INC filings

Eyepoint Pharmaceuticals, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
EYPT
Eyepoint Pharmaceuticals, INC
DEFA14A: EyePoint Pharmaceuticals Corrects Equity Overhang Figure in Proxy Statement
EyePoint Pharmaceuticals issues a supplement to its definitive proxy statement to correct an error regarding the company's equity overhang.
NASDAQ
EYPT
Eyepoint Pharmaceuticals, INC
DEFA14A: EyePoint Pharmaceuticals Sets Date for Annual Stockholders Meeting, Proposes Incentive Plan Amendment
EyePoint Pharmaceuticals will hold its annual stockholders meeting virtually on June 18, 2025, to vote on director elections, an incentive plan amendment, executive compensation, and auditor ratification.
NASDAQ
EYPT
Eyepoint Pharmaceuticals, INC
DEF: EyePoint Pharmaceuticals Eyes Blockbuster Potential with DURAVYU Phase 3 Trials, Solid Financial Position
EyePoint Pharmaceuticals reports strong progress in 2024, highlighted by the advancement of DURAVYU, a potential best-in-class sustained delivery therapy, into Phase 3 trials for wet AMD and DME, alongside a robust financial position.
NASDAQ
EYPT
Eyepoint Pharmaceuticals, INC
DEF 14A: EyePoint Pharmaceuticals Seeks Stockholder Approval for Incentive Plan and ESPP Amendments
EyePoint Pharmaceuticals is asking stockholders to approve amendments to its long-term incentive plan and employee stock purchase plan at the upcoming annual meeting.
NASDAQ
EYPT
Eyepoint Pharmaceuticals, INC
DEFA14A: EyePoint Pharmaceuticals Files Definitive Proxy Statement
EyePoint Pharmaceuticals has filed a definitive proxy statement with the SEC.